JP2024533923A - 点眼投与により白内障を予防および／または治療するための眼科用製剤 - Google Patents

点眼投与により白内障を予防および／または治療するための眼科用製剤 Download PDF

Info

Publication number
JP2024533923A
JP2024533923A JP2023565316A JP2023565316A JP2024533923A JP 2024533923 A JP2024533923 A JP 2024533923A JP 2023565316 A JP2023565316 A JP 2023565316A JP 2023565316 A JP2023565316 A JP 2023565316A JP 2024533923 A JP2024533923 A JP 2024533923A
Authority
JP
Japan
Prior art keywords
content
povidone
lanosterol
solvent
lens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023565316A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024533923A5 (https=
Inventor
チン ドン
ルービン シュエ
Original Assignee
チョンドゥー ルイムー バイオファーマスーティカルズ カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by チョンドゥー ルイムー バイオファーマスーティカルズ カンパニー リミテッド filed Critical チョンドゥー ルイムー バイオファーマスーティカルズ カンパニー リミテッド
Publication of JP2024533923A publication Critical patent/JP2024533923A/ja
Publication of JP2024533923A5 publication Critical patent/JP2024533923A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023565316A 2021-09-03 2022-09-01 点眼投与により白内障を予防および／または治療するための眼科用製剤 Pending JP2024533923A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202111033229 2021-09-03
CN202111033229.1 2021-09-03
PCT/CN2022/116432 WO2023030430A1 (zh) 2021-09-03 2022-09-01 一种滴眼给药预防和/或治疗白内障的眼用制剂

Publications (2)

Publication Number Publication Date
JP2024533923A true JP2024533923A (ja) 2024-09-18
JP2024533923A5 JP2024533923A5 (https=) 2025-08-28

Family

ID=85349262

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023565316A Pending JP2024533923A (ja) 2021-09-03 2022-09-01 点眼投与により白内障を予防および／または治療するための眼科用製剤

Country Status (5)

Country Link
US (1) US20250000791A1 (https=)
EP (1) EP4397302A4 (https=)
JP (1) JP2024533923A (https=)
CN (1) CN115737654B (https=)
WO (1) WO2023030430A1 (https=)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008027340A2 (en) * 2006-08-30 2008-03-06 Merck & Co., Inc. Topical ophthalmic formulations
BRPI0909797A2 (pt) * 2008-03-07 2017-08-22 Sun Pharma Advanced Res Co Ltd Composição oftálmica
CN102048725B (zh) * 2009-10-29 2014-07-16 中国医学科学院药物研究所 紫杉醇胆固醇复合物
US20170239273A1 (en) * 2014-08-22 2017-08-24 Kang Zhang Compositions and methods to treat and/or prevent vision disorders of the lens of the eye
SG11201701377YA (en) 2014-08-22 2017-03-30 Kang Zhang Compositions and methods to treat vision disorders
JP2018522070A (ja) * 2015-07-27 2018-08-09 キャタコア・インコーポレイテッドＣａｔａｃｏｒｅ， Ｉｎｃ． 白内障の処置用組成物
CN109481392B (zh) * 2015-09-02 2021-12-24 盛世泰科生物医药技术(苏州)有限公司 一种用于预防和治疗白内障的眼用制剂及其制备方法
CA2998134A1 (en) * 2015-09-08 2017-03-16 Viewpoint Therapeutics, Inc. Compounds and formulations for treating ophthalmic diseases
CN106344587A (zh) * 2016-08-24 2017-01-25 上海毕傲图生物科技有限公司 羊毛甾醇类化合物眼用制剂
CN107397745A (zh) * 2016-08-24 2017-11-28 上海毕傲图生物科技有限公司 唑类化合物眼用制剂
US20200281944A1 (en) * 2017-11-17 2020-09-10 Mahmood Piraee Combinations Of Lanosterol Or 25-Hydroxycholesterol Including Derivatives Thereof Useful In The Treatment Of Lens Disorders
WO2020020306A1 (zh) * 2018-07-25 2020-01-30 中山大学中山眼科中心 一种羊毛甾醇前药化合物的晶型及其应用
CN110664757B (zh) * 2018-11-19 2022-08-02 成都瑞沐生物医药科技有限公司 纳米晶滴眼剂、其制备方法及其应用
WO2020177714A1 (zh) * 2019-03-04 2020-09-10 中山大学中山眼科中心 一种羊毛甾醇前药化合物的组合物及其制备方法和应用
US20200360403A1 (en) 2019-05-16 2020-11-19 Joseph Domenic SCIAMANNA Opthalmic compositions for inhibiting clouding of the ocular lens

Also Published As

Publication number Publication date
CN115737654B (zh) 2025-11-21
CN115737654A (zh) 2023-03-07
WO2023030430A1 (zh) 2023-03-09
EP4397302A1 (en) 2024-07-10
US20250000791A1 (en) 2025-01-02
EP4397302A4 (en) 2025-08-06

Similar Documents

Publication Publication Date Title
EP2346520B1 (en) Curcuminoids and its metabolites for the application in ocular diseases
EP2965761B1 (en) Meloxicam eye drops and preparation method and use thereof
EP4424302A1 (en) Ophthalmic preparation of tyrosine kinase inhibitor, and preparation method therefor and use thereof
CN115837027A (zh) 一种眼用地塞米松药物组合物
JP2022062172A (ja) 無菌眼用水性プロピオン酸フルチカゾンａ型ナノ結晶懸濁液の調製方法
Sun et al. A simple but novel glycymicelle ophthalmic solution based on two approved drugs empagliflozin and glycyrrhizin: in vitro/in vivo experimental evaluation for the treatment of corneal alkali burns
CN101773468A (zh) 扎那米韦鼻用纳米混悬剂及其制备方法
JP2024533923A (ja) 点眼投与により白内障を予防および／または治療するための眼科用製剤
CN113797163B (zh) 一种滴眼给药防治干性黄斑病变和视网膜光损伤的眼用制剂
CN112294761A (zh) 一种难溶性药物的眼用胶束制剂
CN113350284A (zh) 一种紫檀芪纳米滴眼液及其制备方法
Fang et al. Ion-sensitive in-situ gel loaded with rebamipide micelles for the treatment of diabetic keratopathy
EP4282402A1 (en) Ophthalmic preparation for treating macular edema, optic neuritis and non-infectious endophthalmitis through eye drop administration
Lorenzo Veiga Cyclodextrin nanostructures and ocular drug delivery
US20260108505A1 (en) Eye drop composition comprising novel molecular association of axitinib and method for preparing the same
WO2025144421A1 (en) Aqueous nanomicelle ophthalmic formulations containing difluprednate
HK40077423B (zh) 用於制备无菌眼用水性丙酸氟替卡松a型纳米晶体混悬液的方法
CN117959316A (zh) 一种包含恩格列净的药物组合物及其制备方法与制药用途
HK1234413B (zh) 用於治療眼部病症的膜附著性自組裝體系

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250820

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250820

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20260422